Study shows HIV-exposed children at high risk of language delay

January 10, 2012 By Robert Bock and John McGrath

(Medical Xpress) -- Children exposed to HIV before birth are at risk for language impairments, according to a study by researchers at the National Institutes of Health and other institutions.

Moreover, children exposed to HIV before birth may benefit from for language impairment, even if they don’t have any obvious signs of a language problem, the researchers said.

The researchers found that 35 percent of a group of school-age children born to women with an HIV infection during pregnancy have difficulty understanding spoken words and expressing themselves verbally. On a standard series of tests of language ability, children exposed to HIV before birth scored, on average, within the lowest 21 percent of all children who have taken the test.

Children exposed to HIV before birth tended to have language delays, regardless of whether or not they later became infected with HIV.

"Our results show that children exposed to HIV have more than twice the chance of having a language impairment than do children in the general population," said George K. Siberry, M.D., M.P.H., of the Pediatric, Adolescent and Maternal AIDS Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), one of eight NIH institutes that supported the research.

The study could not determine if the high rates of language impairment in the HIV-exposed children can be attributed to HIV exposure or to other unidentified factors, such as their family status, maternal substance use, environment, or social or economic background.

Funding for the study was also provided by the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the National Institute on Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke.

First author Mabel L. Rice, Ph.D., of the University of Kansas, Lawrence, collaborated with Dr. Siberry and other researchers participating in the NICHD-funded Pediatric HIV/AIDS Cohort Study.

Their findings appear in the Journal of Development and Behavioral Pediatrics.

The 468 children in the study were 7 to 16 years old. A total of 306 were HIV-infected, while the remaining 162 were exposed to HIV during pregnancy but did not become HIV-infected. In addition to evaluating the children’s language ability, the researchers analyzed their medical records, tested their hearing and evaluated their general cognitive development.

Based on the results of this analysis, the children were classified into three groups:

• Those with no language impairment, 65 percent
• Those with a concurrent language impairment (also having a hearing or cognitive impairment), 24 percent
• Those with a primary language impairment (no hearing or cognitive impairment), 11 percent.

Among HIV-positive students, those with a severe or poorly controlled HIV infection were about three times more likely than students with HIV who responded to treatment to experience language delays associated with cognitive impairments or hearing loss.

The researchers encouraged those caring for children exposed to in the womb to provide early treatment for language impairments. Children who don’t use language well not only are at risk for school failure, but may have difficulty communicating with their peers and establishing friendships. Signs of potential include difficulty following instructions, appearing distracted or uninterested, difficulty understanding puns and plays on words, and difficulty with rhyming.

Explore further: Cholesterol levels elevated in toddlers taking anti-HIV drugs

Related Stories

Cholesterol levels elevated in toddlers taking anti-HIV drugs

November 22, 2011
(Medical Xpress) -- Toddlers receiving anti-HIV drugs have higher cholesterol levels, on average, than do their peers who do not have HIV, according to researchers at the National Institutes of Health and other institutions.

Drug to treat HIV in children shows promise via national study

January 9, 2012
(Medical Xpress) -- For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.